698 related articles for article (PubMed ID: 20195520)
21. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
[TBL] [Abstract][Full Text] [Related]
22. Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
Tan GS; Leon PE; Albrecht RA; Margine I; Hirsh A; Bahl J; Krammer F
PLoS Pathog; 2016 Apr; 12(4):e1005578. PubMed ID: 27081859
[TBL] [Abstract][Full Text] [Related]
23. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
[TBL] [Abstract][Full Text] [Related]
24. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
Allen JD; Ross TM
J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
[TBL] [Abstract][Full Text] [Related]
25. Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.
Hervé PL; Lorin V; Jouvion G; Da Costa B; Escriou N
Virology; 2015 Dec; 486():134-45. PubMed ID: 26433051
[TBL] [Abstract][Full Text] [Related]
26. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
[TBL] [Abstract][Full Text] [Related]
27. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.
Margine I; Hai R; Albrecht RA; Obermoser G; Harrod AC; Banchereau J; Palucka K; García-Sastre A; Palese P; Treanor JJ; Krammer F
J Virol; 2013 Apr; 87(8):4728-37. PubMed ID: 23408625
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
[TBL] [Abstract][Full Text] [Related]
30. Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.
Broecker F; Liu STH; Sun W; Krammer F; Simon V; Palese P
J Virol; 2018 Oct; 92(20):. PubMed ID: 30045991
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Next-Generation H3 Influenza Vaccines in Ferrets Pre-Immune to Historical H3N2 Viruses.
Allen JD; Ross TM
Front Immunol; 2021; 12():707339. PubMed ID: 34475872
[TBL] [Abstract][Full Text] [Related]
32. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
Front Immunol; 2018; 9():2350. PubMed ID: 30369928
[TBL] [Abstract][Full Text] [Related]
33. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.
Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F
mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832
[TBL] [Abstract][Full Text] [Related]
34. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.
Bangaru S; Zhang H; Gilchuk IM; Voss TG; Irving RP; Gilchuk P; Matta P; Zhu X; Lang S; Nieusma T; Richt JA; Albrecht RA; Vanderven HA; Bombardi R; Kent SJ; Ward AB; Wilson IA; Crowe JE
Nat Commun; 2018 Jul; 9(1):2669. PubMed ID: 29991715
[TBL] [Abstract][Full Text] [Related]
35. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.
Tan GS; Krammer F; Eggink D; Kongchanagul A; Moran TM; Palese P
J Virol; 2012 Jun; 86(11):6179-88. PubMed ID: 22491456
[TBL] [Abstract][Full Text] [Related]
36. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003.
Okada J; Ohshima N; Kubota-Koketsu R; Ota S; Takase W; Azuma M; Iba Y; Nakagawa N; Yoshikawa T; Nakajima Y; Ishikawa T; Asano Y; Okuno Y; Kurosawa Y
Virology; 2010 Feb; 397(2):322-30. PubMed ID: 19969317
[TBL] [Abstract][Full Text] [Related]
38. Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs.
Xu J; Huang D; Liu S; Lin H; Zhu H; Liu B; Lu C
Virus Res; 2012 Aug; 167(2):188-95. PubMed ID: 22584406
[TBL] [Abstract][Full Text] [Related]
39. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.
Shen C; Zhang M; Chen Y; Zhang L; Wang G; Chen J; Chen S; Li Z; Wei F; Chen J; Yang K; Guo S; Wang Y; Zheng Q; Yu H; Luo W; Zhang J; Chen H; Chen Y; Xia N
Theranostics; 2019; 9(1):210-231. PubMed ID: 30662563
[TBL] [Abstract][Full Text] [Related]
40. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
